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Abstract: Malignant gliomas represent the majority of primary brain tumors, and the prognosis 
of the patients afﬂ  icted with these tumors has been historically dismal, with almost uniform 
progressive neurologic impairment and rapid death. Even with multimodal treatment using 
surgery, focal radiation, and chemotherapy, no major strides were made until recently. The 
development of interstitial BCNU wafers (carmustine wafers, Gliadel®) has led to promising 
results in the treatment of a selected patients with malignant gliomas, as well as with other 
intracranial malignancies.BCNU is one of the ﬁ  rst systemic chemotherapies which had obtained 
United States Food and Drug Administration (FDA) approval for the treatment of brain tumors. 
However, systemic use has been hampered by the modest prolongation of survival and by the 
prolonged myelosuppression and potentially fatal pulmonary toxicity. The development of 
interstitial therapies with BCNU represented a great step forward, allowing direct delivery to the 
tumor bed, with virtually no systemic toxicities. Clinical studies of BCNU wafers have showed 
good efﬁ  cacy in both newly diagnosed and recurrent gliomas, as well as a possible therapeutic 
role in other primary or secondary intracranial malignancies. New studies are currently underway 
trying to improve the efﬁ  cacy of the BCNU wafers (Gliadel®) by combining them with different 
systemic chemotherapies. An overview of the current knowledge ranging from the preclinical 
developments, to the efﬁ  cacy and safety seen in the clinical trials and in clinical practice following 
the drug approval to the future avenues of research is therefore timely.
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Introduction
Glioblastoma multiforme (GBM) is the most common primary neoplasm of the brain, 
which affects approximately 10,000 people every year in the United States (Central 
Brain Tumor Registry of the United States 2004–2005). It is a very aggressive tumor 
(WHO grade IV), with a historical survival of less the one year, which has changed little 
over the last two decades (Ohgaki and Kleihues 2005). Multiple attempts have been 
made to identify effective treatment, leading to the recognition of focal radiotherapy 
and adjuvant chemotherapy with alkylating agents as modalities which modestly 
improve patient survival (Selker et al 2002; Stewart 2002; Stupp et al 2005). However, 
the protective environment of the CNS limits the delivery of the chemotherapy agents 
inside the brain tumor, with many drugs failing to achieve therapeutic concentrations 
at the tumor site, even while the systemic levels are at toxic range.
In order to achieve effective local delivery with minimal systemic side-effects 
different approaches are currently employed, such as administration of therapeutic 
molecules via intracranially implanted catheters, convection-enhanced drug delivery, 
or administration through controlled-release polymers (Raza et al 2005). The ﬁ  rst of 
these new agents to be approved by the United States Food and Drug Administration Therapeutics and Clinical Risk Management 2007:3(5) 708
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(FDA) for the treatment of malignant gliomas is the 1,3-
bis(2-chloroethyl)-1-nitrosurea (BCNU, carmustine) implant, 
also known as the Gliadel® (MGI Pharma, Inc.) wafer.
Preclinical data show that the interstitial release of BCNU 
leads to superior survival when compared with systemic 
administration in gliosarcoma intracranial models (Tamargo 
et al 1993), with minimal release of the BCNU in the sys-
temic circulation (Domb et al 1995). Among the numerous 
polymer matrices studied, polifeprosan 20, a copolymer of 
1,3-bis-(p-carboxyphenoxy) propane and sebacic acid in a 
20:80 molar ratio, was proven to be the most appropriate for 
BCNU delivery, due to the fact that it protected the BCNU 
from hydrolytic degradation before release (Fleming and 
Saltzman 2002), and was safe in primate brain when given 
with focal radiation (Brem et al 1994).
In phase 1 and 2 clinical trials the BCNU wafers were well 
tolerated, with a complication rate acceptable when compared 
with that of the patients receiving placebo wafers, and 
demonstrated activity against new and recurrent malignant 
gliomas (Brem et al 1991, 1995a; Olivi et al 2003). Results of 
these trials showed that BCNU delivery from the polifeprosan 
20 wafers is well tolerated, and has established a safe dose 
of 7.7 mg of BCNU per wafer (3.85% carmustine loading) 
(Olivi et al 2003). At this dose, the local side-effects such 
as brain necrosis and edema are rare, and there is minimal, 
if any, systemic toxicity (Brem et al 1991, 1995a; Olivi et al 
2003).
The BCNU wafers were also evaluated in three random-
ized phase III studies, the initial one focusing on recurrent 
malignant gliomas (Brem et al 1995b), and the subsequent 
two in newly diagnosed patients with malignant gliomas 
(Valtonen et al 1997; Westphal et al 2003). All three clini-
cal trials demonstrated a statistically signiﬁ  cant survival 
advantage for the patients in the BCNU wafers groups. On 
the basis of these results, the BCNU wafers received FDA 
approval for patients with recurrent or newly diagnosed 
anaplastic astrocytomas and glioblastoma multiforme. This 
article reviews the mechanism of action of BCNU, the pre-
clinical development of the BCNU wafers for interstitial 
delivery, and summarizes the results of the clinical trials of 
BCNU wafers for the treatment of malignant gliomas and 
other intracranial malignancies.
Background
More then 40 years ago studies carried by the National Cancer 
Institute led to the development of the initial nitrosurea 
compounds shown to have activity in animal cancer models 
(Johnston et al 1963), with the ﬁ  rst successful formulation 
being 1-methyl-3-nitro-1-nitrosoguanidine (Schepartz 
1976). The interest in ﬁ  nding more active analogs led to 
the discovery in 1963 of 1,3-bis(2-chloroethyl)-1-nitrosurea 
(BCNU, carmustine), an agent proven to be highly effective 
not only in the intraperitoneal L1210 murine leukemia, but 
also in the treatment of intracerebral L1210. This activity 
in the intracranial site was felt to be secondary to its ability 
to cross the blood–brain barrier (Schabel et al 1963). One 
year later, BCNU was introduced in clinical trials (Loo et al 
1966; Weiss and Issell 1982) and was approved by the FDA 
in March 1977 for the treatment of brain tumors, Hodgkin’s 
disease, and other hematologic malignancies. This led to one 
of the ﬁ  rst effective therapies for human malignant gliomas 
in clinical trials (Chang et al 1983; Green et al 1983; Selker 
et al 2002), with a survival advantage of 2 months compared 
with patients who received radiation alone (Stewart 2002). 
At the same time, BCNU toxicity secondary to systemic 
administration became well described, with frequent dose-
limiting delayed hematologic toxicity (De Vita et al 1965), 
non-dose-dependent pulmonary ﬁ  brosis (Crittenden et al 
1977; Litam et al 1981), and secondary acute leukemia in 
5%–10% of the patients (Cohen et al 1976; Michels et al 
1985). Further research work also showed that the systemic 
and intrathecal delivery of BCNU produced penetration for 
a very short distance (2 mm from the ependymal surface) 
and started the quest for better delivery systems (Blasberg 
et al 1975).
Direct administration of BCNU through a catheter 
inserted in the surgical cavity was initially attempted in 1975, 
with no clear success, presumably secondary to the short half-
life of BCNU in solution (Loo et al 1966) and to the limited 
delivery to the tumor tissue (Garﬁ  eld et al 1975).
Biodegradable polymer wafers for the delivery of BCNU 
in malignant gliomas were developed by Henry Brem and 
his group, starting in the late 1980s (Yang et al 1989). This 
delivery system was proven superior to the systemic adminis-
tration in animal models, and demonstrated limited systemic 
toxicity (Tamargo et al 1993), providing the rationale for 
evaluation in patients.
Pharmacology and preclinical data
BCNU mechanism of action, 
pharmacokinetics, and activity
Though considered to be an alkylating agent, BCNU differs 
from the other derivatives by having several reaction sites in 
addition to the carbon–chlorine bond, which are able to inter-
act with a variety of reagents under physiological conditions 
(Loo et al 1966). Its cytostatic properties are secondary to Therapeutics and Clinical Risk Management 2007:3(5) 709
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its inhibitory effects at multiple levels, such as DNA (Kohn 
1977), RNA (Grimmond and Zirvi 1987) and protein synthesis 
(Penman et al 1976; Weiss and Issell 1982). In vitro, BCNU 
has shown activity against cell lines derived from numerous 
malignancies, including leukemia (Schabel 1973), lung can-
cers, sarcomas, and gliomas (Carter et al 1972).
The main BCNU effect is mediated by its chloroethyl 
moieties, which can alkylate reactive sites on nucleoproteins 
(Woolley et al 1976), and interfere with DNA synthesis and 
repair (Weiss and Issell 1982). DNA cross-linking occurs 
in two steps: chloroethylation of a nucleophilic site on one 
strand, and displacement of a chloride ion on the other strand, 
resulting in formation of an ethyl bridge between the strands, 
which blocks the DNA unwinding, and consequently DNA 
and RNA synthesis (Kohn 1977). The high alkylating activity 
of BCNU is also the cause of its main side-effects, interstitial 
pneumonitis, due to the DNA injury to the alveolar lining 
cells (Weiss et al 1981) and suppression of hematopoeisis 
(Lohrmann et al 1982). Another mechanism of activity is 
the carbomoylation of nucleoprotein lysine residues, with 
subsequent decrease in RNA and protein synthesis. The 
importance of this process in the antitumor effect of BCNU 
is still debated (Kann 1978).
After both oral and intravenous administration, BCNU 
has a very short life, with the parent drug not being detectable 
after 5 minutes (Oliverio 1976), and its active metabolites 
being detected in urine up to 72 hours after the initial dose. 
Both the parent drug and its metabolites rapidly enter the 
cerebrospinal ﬂ  uid (CSF) (De Vita et al 1967). The preclini-
cal studies also showed wide distribution, with good CSF 
penetrance (Loo et al 1966), and activity in transplanted 
gliomas, ependymoblastomas, and astrocytomas (Schabel 
1976). However, BCNU penetration inside the brain tissue 
was just for a very short distance (2 mm from the ependymal 
surface) (Blasberg et al 1975).
BCNU interstitial delivery
with biodegradable matrices
A number of different polymers were studied in order to 
determine their bio-compatibility and to be able to achieve 
the graduated, controlled release of BCNU in the tumor 
tissue. A direct comparison between ethylene-vinyl acetate 
copolymer and the poly(carboxyphenoxy-propane/sebacic 
acid) matrices in rats showed that both polymers were 
well tolerated, and effective in delivering the BCNU, with 
a signiﬁ  cant increase in animal survival (Tamargo et al 
1993). The poly(carboxyphenoxy-propane/sebacic acid) 
matrix was chosen as the foundation for the Gliadel® wafers. 
Pharmacological studies showed that the Gliadel® wafers 
release BCNU in vivo over a period of 21 days, the majority 
of the drug release taking place in the ﬁ  rst 5–7 days (Gross-
man et al 1992; Domb et al 1995), and degrade completely 
over a period of 6–8 weeks, with the polymer degradation 
products being eliminated through the urine (Grossman 
et al 1992;  Wu et al 1994; Dang et al 1996). The BCNU-
polifeprosan 20 wafers allowed delivery of BCNU at high 
concentrations up to 12 mm from the polymer site in animal 
models (Grossman et al 1992), while distant regions of the 
brain are exposed only to very low concentrations (Fleming 
and Saltzman 2002).
Mechanism of resistance
The resistance to BCNU is complex, due to the fact that 
at least two types of DNA lesions are created: chloroethyl 
adducts at O6-guanine and interstrand cross-links (Drablos 
et al 2004). The repair of the chloroethyl adducts is conducted 
by O6-alkylguanine-DNA alkyltransferase (AGT or MGMT). 
AGT activity has been proven to be a major factor in the 
resistance to BCNU and to other alkylating agents including 
methylators, as cells that have a low level of AGT are sensi-
tive to alkylating agents, while cells expressing high levels 
are resistant (Pegg et al 1995; Friedman et al 1998b; Hegi 
et al 2004). The administration of O6-substituted guanines 
such as O6-benzylguanine (O6BG) can effectively deplete the 
AGT and restore cell sensitivity to BCNU in both cell cultures 
(Friedman et al 1992) and xenograft models of malignant 
gliomas (Felker et al 1993).
The repair of the second type of lesions, DNA interstrand 
cross-links, needs the presence of nucleotide excision repair 
and homologous recombination factors (McHugh et al 2001), 
but the contribution of these repair mechanisms to BCNU 
resistance is not well understood.
Clinical experience with Gliadel® 
in malignant gliomas
Initial phase I studies
Recurrent malignant gliomas
The initial phase I study to determine the optimal concentra-
tion of BCNU was done in patients with recurrent malignant 
glioma (Brem et al 1991). The study enrolled 21 patients 
divided into 3 sequential groups to receive up to 8 wafers of 
increasing BCNU concentrations (1.93%, 3.85%, and 6.35%). 
All the patients had maximum tumor resection at the time of 
placement of the BCNU wafers. The three groups had similar 
demographics, but the ﬁ  rst two groups had 60% GBM patients, 
while the highest dose group contained only GBM patients. All Therapeutics and Clinical Risk Management 2007:3(5) 710
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three concentrations had similar local side-effects, with 13 out 
of the 21 patients having new areas of contrast enhancement 
around the resection cavity at least 7 weeks after the surgery 
and 10 patients out of 21 needed surgeries for decompression 
and removal of necrotic tissue. No systemic side-effects were 
noted. The post-implant and overall survival were higher in 
the two lower-dose groups then in the high-dose group, which 
can be at least partially explained by the higher percentage of 
patients with GBM in the third group. In consequence, the 
3.85% BCNU was chosen as the standard dose to be used in 
the phase III clinical trials and marketing.
A second escalation study in recurrent malignant gliomas 
was conducted by the New Approaches to Brain Tumor 
Therapy (NABTT) CNS Consortium (Olivi et al 2003). This 
study enrolled 44 patients with recurrent disease, all of which 
had received prior external beam radiation. These patients were 
divided in 5 cohorts to be implanted with wafers containing 6.5%, 
10%, 14.5%, 20%, and 28% BCNU concentration per 200 mg 
wafer. In the 6.5 %, 10%, and 14%, no dose-limiting toxicities 
were observed, and the adverse events (subdural collection, CSF 
leak, sepsis, and wound infection) were regarded to be similar 
to those in the patients subjected to tumor re-resection alone. 
The 20% dose cohort also had similar side-effects (seizures, 
brain edema, wound infection, wound drainage, and a bone ﬂ  ap 
infection). However, three out of the four patients enrolled in the 
28% dose cohort developed major brain edema and seizures, and 
the 20% dose level was conﬁ  rmed as the maximum tolerated 
dose. However, at the 20% dose level, the BCNU concentration 
in the blood reached 27 ng/mL at 4 hours after delivery. No 
systemic toxicities were included in this study report.
Newly diagnosed malignant gliomas
A phase I trial was also conducted in the newly diagnosed glio-
mas at the same institutions involved in the initial phase I study 
for recurrent gliomas (Brem et al 1995a). This trial enrolled 22 
patients who received maximum resection, placement of seven 
to eight wafers impregnated with 3.85% BCNU, and subsequent 
standard external beam radiation. Ten of the 22 patients experi-
enced severe adverse-effects in the postoperative period, such as 
seizures, neurologic decline, brain necrosis, infection, and deep 
venous thrombosis. Nine patients needed a secondary craniotomy 
after an average of 34 weeks, but 8 had recurrent tumor and only 
1 necrosis. The median survival was 42 weeks.
Phase I and III clinical experience
Based on the safety data from the phase I and II clinical trials, 
and the need for improved treatment in malignant gliomas, a 
series of phase III clinical trials were conducted.
Recurrent malignant gliomas
The initial phase III study (Brem et al 1995b) enrolled 222 
patients with recurrent malignant glioma who had an unilat-
eral single focus of recurrent tumor of at least 1 cm3, a KPS 
>60%, and no recent treatment with nitrosureas. Patients were 
implanted with either the carmustine polymer or the placebo 
polymer disks. The dose of carmustine on the polymer disks 
was 7.7 mg per wafer (3.85% BCNU). The median survival 
for the combined pathology (anaplastic astroccytoma and 
glioblastoma multiforme) was 31 weeks in the carmustine 
group and 23 weeks in the placebo group (survival advantage 
of 8 weeks). For the patients diagnosed with glioblastoma 
multiforme the 6 months survival was 56% in the carmustine 
group and 47% in the placebo group (p = 0.061). The only 
complication more frequently seen in the treatment group 
was serious intracranial infection. Based on the results of 
this study US-FDA approval of Gliadel® for the treatment 
of recurrent patients was obtained in 1996.
Newly diagnosed malignant gliomas
The ﬁ  rst phase III study of carmustine loaded polymers for 
newly diagnosed patients (Valtonen et al 1997) enrolled 32 
newly diagnosed patients (initial enrollment planned for 100 
patients) with grade III and IV gliomas. The inclusion criteria 
required unilateral disease greater than 1 cm3, not crossing 
the midline, and good performance status. The patients were 
randomized to receive BCNU or placebo wafers, after which 
they underwent standard focal beam radiation therapy. No 
indication of adjuvant treatment was provided. The time 
from surgery to death was the primary endpoint, with a 
median survival time of 58.1 weeks for BCNU vs 39.9 for 
placebo, with a survival advantage of 18 weeks (p = 0.012). 
The adverse effects were comparable between these two 
groups, and included wound infection, septic inﬂ  ammation 
with meningismus, CSF leukocytosis with hydrocephalus, 
deep venous thrombosis with pulmonary thromboembolism, 
pneumonia, visual disturbances, and hemiparesis.
A larger phase III study to conﬁ  rm the previous data 
enrolled 240 patients from 38 centers in 14 countries 
(Westphal et al 2003). The patients were again randomized 
to be implanted with BCNU vs placebo wafers, followed by 
focal radiation, while adjuvant systemic chemotherapy was 
explicitly prohibited until the time of tumor recurrence. The 
patient follow-up reported in this study was between 12 and 
30 months. The median survival in the intent-to-treat group 
(grade III and IV tumors) was 13.9 months for the patients 
receiving BCNU wafers vs 11.6 months for the placebo 
group (p = 0.03). The GBM subgroup multivariate analysis Therapeutics and Clinical Risk Management 2007:3(5) 711
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showed that BCNU wafers prolonged survival in the treat-
ment group, after correction for prognosis factors (p = 0.04), 
with a risk reduction of 31% (95% CI, 3%–51%). More CSF 
leaks and increased intracranial pressure secondary to mass 
effect and edema were seen in the BCNU-wafer-treated 
group. It is important to mention that this study had targeted 
a selected population, as a retrospective review of the patients 
enrolled from the Edinburgh center showed that only 25% 
of the patients with malignant glioma could be enrolled in 
the trial, and that they were younger, had better performance 
status, and were more likely to have tumor resection and 
postoperative radiotherapy (Whittle et al 2003).
A long-term report (56 months follow-up period) including 
data on the patients still alive at the time of publication of the 
phase III study conﬁ  rmed a median survival of 13.8 months vs 
11.6 months (p = 0.017) in favor of the BCNU-wafer-treated 
group, and a continuous survival advantage at 1, 2, and 3 years 
(Westphal et al 2006). The report of the pattern of recurrence 
in a subgroup of 24 patients from the Westphal study showed 
a time to progression of 165 days for the patients in the BCNU 
wafers group vs 101 days for the placebo group (p = 0.023) 
(Giese et al 2004). All the patients receiving BCNU wafers 
eventually had recurrent tumor, with 73% of the patients hav-
ing recurrent tumor adjacent to the resection cavity, and 27% 
having both local and distal recurrences.
A meta-analysis combining two phase III clinical trials 
for newly diagnosed patients (Valtonen et al 1997; Westphal 
et al 2003) has also been reported (Meldorf et al 2003). The 
meta-analysis included all the patients diagnosed with GBM, 
and reported a median survival for the Gliadel® group of 13.1 
months vs 10.9 months for the placebo group (p = 0.031), 
and a hazard ratio of 0.71 (p = 0.019) at the multivariant 
analysis, which translates in a 29% reduction in the risk 
of dying. The results of this meta-analysis led to the FDA 
approval of Gliadel® for newly diagnosed high grade glioma 
patients in 2003.
Complications
A number of complications related to the Gliadel® wafers 
were identiﬁ  ed during the phase III clinical trials, but the 
rate was similar to that in patients receiving placebo wafers 
(Valtonen et al 1997; Westphal et al 2003). However, 
in clinical practice following the drug approval, more 
treatment-related complications were identiﬁ  ed, as the 
treatment was extended also to patients who were not 
eligible in the initial studies.
The rate of postcraniotomy surgical infection after BCNU 
wafer placement was reported to be as high as 28%, and is 
correlated with inadequate antibiotic prophylaxis (McGovern 
et al 2003). Extensive cerebral edema was also reported after 
Gliadel® placement, and led to severe neurologic compromise 
and death (Weber and Goebel 2005). Another cause of severe 
toxicity and death with Gliadel® wafers recently reported is 
obstructing hydrocephalus, and the authors of the case-report 
concluded that a large opening of the ventricle during surgery 
might be considered a contraindication for wafer placement 
(Gallego et al 2007).
Local treatment effects, such as pericavity necrosis are 
also commonly seen, affecting 11% of all patients, and 33% 
of the patients undergoing re-operation for radiological pro-
gression, which it makes difﬁ  cult to differentiate between 
tumor recurrence and treatment effect based on non-invasive 
studies (Kleinberg et al 2004). Other observations following 
Gliadel® implantation include the formation of tumor bed 
cysts with new neurologic symptoms secondary to mass 
effect. This complication has been addressed successfully with 
either high dose steroids or surgical decompression depending 
on the degree of mass effect (McGirt et al 2002).
Overcoming resistance – combination 
trials
Due to the clear survival advantage in a well deﬁ  ned group 
of patients with new and recurrent malignant gliomas, new 
strategies were developed in order to augment the therapeutic 
effect of the BCNU wafers by decreasing the tumor resistance 
to alkylating agents mediated by AGT or by combining the 
BCNU wafers with either systemic chemotherapeutic agents 
such as temozolomide, carboplatin, PCV, and irinotecan or 
other interstitial therapies such as interleukin-2, iodine-125 
seeds, GliaSite® (Cytyc Corp.), and radiosurgery (Ashby 
and Ryken 2006).
Gliadel® and O6Benzylguanine (O6BG)
The initial work in animal models showed that O6BG can 
potentiate the activity of carmustine wafers by inhibiting the 
activity of AGT, a DNA repair enzyme involved in tumor 
resistance to alkylating agents including BCNU, and prolong 
animal survival (Rhines et al 2000). The initial trial of O6BG 
in patients with brain tumors demonstrated suppression of 
AGT activity when O6BG was administered at a dose of 120 
mg/m2 18 hours before surgery (Friedman et al 1998a). Built 
on this, a phase I trial of Gliadel® combined with O6BG has 
demonstrated that the combination is well tolerated when 
O6BG is administred as a 120 mg/m2 bolus 1 hour before 
surgery, followed by continuous infusion at 30 mg/m2/day 
for up to 7 days (Weingart et al 2007). The phase II clinical Therapeutics and Clinical Risk Management 2007:3(5) 712
Bota et al
trial of Gliadel® plus O6BG in recurrent glioblastoma multi-
forme patients from our institution (Quinn et al 2007) used 
a 120 mg/m2 bolus over 1 hour administered after surgery, 
and on day 3 and 5 simultaneously with a 5-day infusion at 
30 mg/m2/day. Preliminary results indicated a 80% 6-month 
survival and 47 weeks median survival, which is signiﬁ  cantly 
better compared with 56% 6-month survival and 31 weeks 
median survival in the original Brem study. The adverse 
effects were similar to those described with Gliadel® alone 
(Quinn et al 2007).
Combination treatment with systemic 
chemotherapy
Gliadel® and temozolomide were shown in separate studies 
to prolong patient’s survival, leading to a phase I study to 
determine the optimal dose of temozolomide to be used in 
patients with recurrent gliomas who had prior placement of 
Gliadel® wafers. Patients tolerated doses up to 200 mg/m2 for 
5 days given every 4 weeks, with only 1 patient developing 
grade III thrombocytopenia, and 2 out of 10 patients had 
no tumor recurrence after 1 year (Gururangan et al 2001). 
A phase II multicenter clinical trial is currently underway for 
patients with newly diagnosed malignant gliomas (LaRocca 
et al 2006). The patients enrolled had resection and Gliadel® 
insertion, followed by focal beam radiation with concomitant 
daily temozolomide (at 75 mg/m2), followed by monthly 
temozolomide (5-day regimen, at 200 mg/m2). At the last 
report, 33 patients were enrolled, with a median follow-up 
of 8.1 months. The median survival is 18.5 months, and the 
median progression-free survival is 6.4 months.
A second phase I study combined Gliadel® wafer implan-
tation with immediate postoperative carboplatin followed by 
radiation therapy in patients with newly diagnosed malignant 
gliomas. Carboplatin dose was calculated based on Calvert 
formula, where the dose of carboplatin (mg) = target area 
under the carboplatin concentration curve vs time curve 
(AUC) × glomerular ﬁ  ltration rate + 25. The maximum toler-
ated dose for carboplatin which was administered on either 
day 3 or 4 after surgery corresponded to an AUC of 6. No 
toxicities were seen (Limentani et al 2005).
The combination of Gliadel® and PVC (procarbazine, 
lomustine, and vincristine) chemotherapy in newly diagnosed 
patients with malignant glioma was explored in the context 
of a phase I/II clinical trial (LaRocca et al 2005). Though a 
small study (9 patients enrolled), the combination seems to 
be tolerated, and possibly effective.
Our group has conducted a retrospective study to 
determine if Gliadel® wafer insertion at the time of initial 
surgery beneﬁ  ted patients receiving radiation therapy with 
concurrent temozolomide, followed by rotational multi-agent 
chemotherapy (temozolomide, CCNU, CPT-11) (Rich et al 
2007). In this study, a difference in survival was found 
between the patients that had Gliadel® wavers vs those that 
had surgery alone.
Finally, in recurrent patients with glioblastoma multiforme, 
the toxicity and efﬁ  cacy of the combination of Gliadel® and 
intravenous irinotecan was reported (Sampath et al 2005a). In 
the 10 patients enrolled, the combination was well tolerated 
and possibly more effective then monotherapy.
Combination treatment with local 
chemotherapy
The combination of Gliadel® and permanent I-125 Seeds 
was addressed in 4 different clinical trials enrolling recurrent 
malignant glioma patients (Foltz et al 2001; Tozer et al 
2003; Darakchiev et al 2004; Zamorano et al 2005). The 
combination was safe, and the major complication was 
radiation necrosis (up to 24% of the patients). The largest 
of these studies (Darakchiev et al 2004) enrolled 34 patients 
with recurrent glioblastoma, and reported a progression-free 
survival of 47 weeks, and overall survival of 73 weeks, which 
compares favorably with the published data on Gliadel® 
monotherapy (Brem et al 1995b).
Consecutive use of brachytherapy (Gliasite®) and 
Gliadel® was studied in a phase I/II study which enrolled 
27 patients with recurrent glioblastoma (Sampath et al 
2005b). The overall median survival was 27 weeks, and the 
complications were rare, but included 1 death (intracranial 
hemorrhage) and 4 thrombotic events (DVT).
Only animal data are available at this time evaluating the 
combination of BCNU wafers with local administration of 
interleukin-2 (IL-2). In the rodent model, the animals that 
received an intracranial implant of microspheres contain-
ing IL-2, followed 5 days later by BCNU wafers showed 
superior survival compared with the animals that received 
either one of the two drugs alone or the placebo implants 
(Rhines et al 2003).
Other tumors
Pituitary adenomas, craniopharingiomas, 
and esthesioblastoma
The results of a phase I feasibility study from University 
of Virginia show that Gliadel® is a reasonable option in the 
treatment of non-glial intracranial tumors such as pituitary 
adenomas and craniopharyngiomas. Among the 10 patients Therapeutics and Clinical Risk Management 2007:3(5) 713
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enrolled in this study, 7 were still alive after a mean follow-up 
of 19 months, with 4 patients free of recurrent tumor, and 2 
with stable disease (Laws et al 2003). No side-effects such as 
CSF leaks were observed in this population, though more than 
half the patients have received either stereotactic radiosurgery 
or conventional focal radiation to the tumor bed.
A case report was also published about the use of car-
mustine wafers in the treatment of esthesioblastomas, with 
good local control and minimum complications (Park et al 
2006). More research needs to be done in order to be able to 
conclude that this treatment is efﬁ  cacious in the treatment 
of this rare tumor.
Metastatic brain tumors
Animal studies from Brem’s group show that Gliadel® in 
combination with radiation is effective against the four meta-
static tumor models tested in the initial study: lung carcinoma, 
renal cell carcinoma, colon carcinoma and melanoma (Ewend 
et al 1996), as well as in a model of breast carcinoma (Ewend 
et al 1998). A newly published phase II study reports on the 
safety and efﬁ  cacy of Gliadel® wafers followed by whole-brain 
radiation for the treatment of single brain metastasis (Ewend 
et al 2007). This treatment achieved superior local control, with 
zero local recurrences and a rate of distal brain relapse of 16%, 
similar to other studies of brain metastasis (Patchell et al 1990, 
1998). Therapy was well tolerated, with 3 severe side-effects 
such as seizures and respiratory compromise, and 7 mild or 
moderate adverse effects (nausea, fever, constipation, and eye 
pain). The median survival was 33 weeks, with 33% survival 
at 1 year, and 25% at 2 years.
Summary and conclusion
BCNU polymeric wafers represent an innovative way of 
delivering chemotherapy directly to the intracerebral high-
grade tumors, with no systemic toxicity. Building on the 
known activity of BCNU as alkylating agent in malignant 
gliomas, it allows for sequential drug release in a constant 
and safe manner in the surrounding brain tissue. This method 
is very well tolerated, with minimal local toxicity.
Clinical trials using Gliadel® have shown that it is a 
valid option in a selected group of patients with malignant 
gliomas (good performance status, only one relatively small 
lesion), in both the new diagnosed and recurrent settings. 
Recent studies are suggesting that the activity of the BCNU 
wafers can be improved by administration of agents that 
overcome resistance to BCNU (such as O6-BG), and the 
results of combination trials with other therapeutic modali-
ties appear promising. More data need to be accumulated in 
order to have a clear understanding of the role of Gliadel® 
in the treatment of other intracranial neoplasms, as well as 
intracranial metastatic disease.
The complications of using the Gliadel® seem to be compa-
rable with those of craniotomy alone, but increased difﬁ  culty 
with wound healing, and rare and potential fatal incidents of ma-
lignant brain edema, as well as of chemical meningitis followed 
by obstructive hydrocephalus, have been reported. Therefore, 
the survival beneﬁ  ts of Gliadel® placement should be balanced 
by the clinician with the concern for possible toxicity.
The limitations of the BCNU wafers are directly related 
to the limited penetrance of BCNU, as most of the tumors 
recur locally, at a short distance from the wafers. Therefore, 
it is critical to evaluate valid systemic treatments, which can 
both address the local and the distant brain involvement, and 
which can be safely used in this setting. A number of promis-
ing multimodal therapies are currently progressing through 
clinical trials, based on the good safety proﬁ  le already dem-
onstrated in the combinations studies of different systemic 
chemotherapeutic agents such as temozolomide, carboplatin, 
PCV, and carboplatin in patients that have received Gliadel® 
(Ashby and Ryken 2006).
In conclusion, the unique properties of the Gliadel®, its 
lack of systemic side-effects, and its documented safety 
and efﬁ  cacy justify its use in malignant gliomas, and its 
potential applications in other intracranial tumors. Large-
scale trials addressing ways to overcome local resistance 
to BCNU, as well as multi-agent chemotherapy combina-
tions, are currently in different stages. Further work needs 
to focus in developing better local delivery systems, with 
improved penetrance in the brain tissue, as well in address-
ing the multifactorial mechanisms of BCNU resistance, 
and in attempting the interstitial delivery of improved 
chemotherapeutic agents.
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